I don't know if this data is sufficient for you, but its the...

First 36 Last

Share
Profile

Follow
yensog

515 Posts.

01/05/16

10:45

Post #: 17644355
Share

Originally posted by Dr.Who ↑

Here's a conspiracy theory for you:

I would very much like to see an analysis of trading over the past year. Over $2000m of market capitalisation has gone somewhere? Who has profited from this?

Could it be associates of the syndicate have been active trading the stock- short and close/long to capture a bounce then short again. There has been bounces, in just four days late 2015 the stock put on well over 130%.

If it was possible to isolate activity involving Slater & Gordon in the books of banking syndicate members what might it reveal? Could profits already achieved through trading activity offset a potential partial forgiveness in debt? Meanwhile the associates might have commenced accumulating stock (medium term not daily trading purpose) since mid 20s ready for the inevitable bounce when the coast is clear. Profit from investing in the reversal after building sizeable (but each entitiy less than 5%) in at the bottom.

Net result (all hypothetical, non of it based on knowledge of the situation just for the purpose of exploration)

Collectively syndicate write-off $500m of debt
Associates achieved profits of $1000m through trading activity
Net result +$500m
Plus
Positioned to profit from upside when the coast is clear.

Personally I don't believe in what I've written above but a small part of me wonders! Finance is no doubt a tangled web.

Expand

I don't know if this data is sufficient for you, but its the best I can get at the moment (from CommSec)

SGH Price at posting: 29.5¢ Sentiment: Hold Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

LU7

Strong PFS numbers solidify Lithium Universe's big plans for Québec

Failure to report prompts ASX to impose multiple company suspensions

IRE

Iress runs 'hot' for Wealth Within's stock tips

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals